Two-Hour Cyclosporine Concentration Determination: An Appropriate Tool to Monitor Neoral Therapy?
- 1 February 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 24 (1) , 40-46
- https://doi.org/10.1097/00007691-200202000-00008
Abstract
Cyclosporine is a critical dose drug for which individualisation by therapeutic drug monitoring is indisputable. Current evidence suggests that a single concentration (C2) taken two hours after cyclosporine administration with the microemulsion formulation better predicts exposure and events than the trough concentration (C0), which is routinely used for adjusting the dosage of this drug. Studies have shown that the greatest calcineurin inhibition and the maximum inhibition of IL-2 production occur in the first 1 to 2 hours after dosing. These findings support the concept that the C2 level better reflects immunosuppressive efficacy than the trough concentration. Preliminary data from an outcome study in liver transplant recipients have shown that the incidence of biopsy proven moderate to severe acute rejection was significantly lower in patients managed by C2 monitoring compared with those monitored by C0. The critical importance of achieving adequate cyclosporine exposure during the first 3 to 5 posttransplant days to prevent acute rejection has been documented in prospective studies with de novo renal and liver transplant recipients. Conversion of maintenance liver and heart transplant patients to C2 monitoring resulted in an amelioration of renal function. Time-dependent target values have been proposed for liver and renal transplant recipients. These require further prospective validation. For routine monitoring of C2 levels on-site validated dilution guidelines are necessary for most of the available immunoassays. C2 monitoring necessitates further organizational requirements which may be judged differently between transplant centers. In particular during the early posttransplant period C2 monitoring is a promising new option to make immunosuppressive therapy with the microemulsion formulation of cyclosporine safer and more efficient.Keywords
This publication has 27 references indexed in Scilit:
- Limited Sampling Strategies for Estimating Cyclosporin Area Under the Concentration–Time Curve: Review of Current AlgorithmsTherapeutic Drug Monitoring, 2001
- New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprineClinical Biochemistry, 2001
- Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996New England Journal of Medicine, 2000
- Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the international neoral® tdm advisory consensus meeting (vancouver, november 1997)Transplantation Proceedings, 1998
- Therapeutic drug monitoring of cyclosporine and tacrolimusClinical Biochemistry, 1998
- Cyclosporine Monitoring in Patients With Renal Transplants: Two- or Three-Point Methods That Estimate Area Under the Curve Are Superior to Trough Levels in Predicting Drug ExposureTherapeutic Drug Monitoring, 1998
- A RANDOMIZED, PROSPECTIVE MULTICENTER PHARMACOEPIDEMIOLOGIC STUDY OF CYCLOSPORINE MICROEMULSION IN STABLE RENAL GRAFT RECIPIENTS1,2,3Transplantation, 1996
- Lake Louise Consensus Conference on Cyclosporin Monitoring in Organ Transplantation: Report of the Consensus PanelTherapeutic Drug Monitoring, 1995
- PHARMACOKINETICS AND TOLERABILITY OF A MICROEMULSION FORMULATION OF CYCLOSPORINE IN RENAL ALLOGRAFT RECIPIENTS—A CONCENTRATION-CONTROLLED COMPARISON WITH THE COMMERCIAL FORMULATIONTransplantation, 1994
- Critical issues in cyclosporine monitoring: report of the Task Force on Cyclosporine Monitoring.Clinical Chemistry, 1987